HCC

This phase 2 trial is testing a combination of three drugs (cabozantinib, ipilimumab, and nivolumab) plus a procedure called TACE in 35 people with liver cancer that cannot be cured by surgery or transplant. The goal is to see if this approach can stop the cancer from growing for…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This study tests a culturally tailored support program for Black patients with early-stage liver cancer. The program includes education, help with social needs, and easier access to cancer specialists. Forty participants will be randomly assigned to the program or usual care and …

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This study looks at whether adding focused radiation to spots where cancer is growing can help people with advanced liver cancer whose first immunotherapy treatment has partly stopped working. About 30 adults with limited new growth will receive radiation to those spots while con…

This clinical trial is testing a new drug called VRT106 combined with two other drugs (camrelizumab and apatinib) in people with advanced liver cancer that has not responded to prior immunotherapy. The study will enroll 66 participants and aims to see if the combination is safe a…

This study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…

This phase 2 trial is testing whether adding precise, high-dose radiation (SBRT) to standard immunotherapy drugs (atezolizumab plus bevacizumab) can help people with advanced liver cancer that has spread into the main portal vein. About 40 participants will receive the combinatio…

This study is testing a new way to deliver radiation therapy for liver cancer. Instead of multiple sessions over weeks, patients receive a single, high-dose treatment guided by real-time MRI scans. The approach aims to be more precise and convenient. The trial will enroll 62 adul…

This phase 2 trial tests whether a combination of radioactive beads (yttrium-90), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib) works better than standard chemoembolization for liver cancer that cannot be surgically removed. About 120 adults with non-met…

This study tests whether treating donor livers with a special oxygen-rich cold fluid (HOPE) before transplant can help prevent liver cancer from returning. About 220 adults with liver cancer waiting for a transplant will be randomly assigned to receive either a standard preserved…

This study tests whether contrast-enhanced ultrasound (CEUS) can better detect if liver cancer (HCC) has been killed by radioembolization treatment. Standard CT or MRI scans often take months to show clear results, delaying further treatment. Researchers will enroll 30 patients a…

This study looks at 1,000 people with alcohol-related liver disease to understand how their genes and drinking habits together raise the risk of liver cancer. Researchers will analyze DNA and lifestyle factors to create a risk score that could help doctors decide who needs regula…

This study looks at how certain genes increase the risk of liver cancer (hepatocellular carcinoma) in people with nonalcoholic fatty liver disease (NAFLD). Researchers will follow 500 adults aged 45-75 with NAFLD to understand how genetic factors and lifestyle interact. The goal …